MEF2A, MEF2C, and MEF2D as potential biomarkers of pancreatic cancer?
Our results indicated that the overexpression of MEF2A, MEF2C, and MEF2D in patients with PAAD. MEF2A could be used as a prognostic biomarker for PAAD, MEF2C might be a potential oncogene for PAAD, and MEF2D had potential biological significance.
Authors
- Fan Yang (ORCID: https://orcid.org/0000-0002-1044-7821)
- Alex Y. Huang (ORCID: https://orcid.org/0000-0002-5701-4521)
- Ge Yang (ORCID: https://orcid.org/0000-0002-7023-9143)
- Liping Mao (ORCID: https://orcid.org/0000-0002-0857-3896)
- Chun-Xia Zhai
- Yi Ding (ORCID: https://orcid.org/0000-0001-7525-7124)
- Xiaorong Ding (ORCID: https://orcid.org/0000-0002-7323-8146)
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1186/s12885-025-14107-x
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Government of Jiangsu Province